Change search
ReferencesLink to record
Permanent link

Direct link
Costs of COPD by disease severity
AstraZeneca Nordic.
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine.
Show others and affiliations
2011 (English)In: European Respiratory Journal, ISSN 0903-1936, E-ISSN 1399-3003, Vol. 38, no Suppl 55Article in journal, Meeting abstract (Refereed) Published
Abstract [en]

Background: Chronic obstructive pulmonary disease (COPD) is one of the most common chronic and disabling diseases worldwide, and the societal costs are high.

Aim: To estimate the societal costs of COPD in Sweden and to examine the relationship between disease severity and costs.

Methods: The study sample was identified in earlier clinical examinations of general population cohorts within the OLIN (Obstructive Lung Disease in Northern Sweden) studies. The cohort consisted initially of 993 subjects fulfilling COPD spirometric criteria (GOLD). In 2009-2010, telephone interviews on resource utilization were made to a sample of 244 subjects, stratified by disease severity. Interviews were performed quarterly to minimize the risk of recall bias. A non-parametric Mann-Whitney U-test was used to test cost differences between groups; p-values adjusted by Bonferroni correction. Unit costs from 2010 were applied.

Results: A highly significant relationship was found between disease severity and costs. The mean annual total cost per patient in relation to disease severity (GOLD) was: stage I €811; II €2,660; III €7,068; and IV €20,665. Indirect costs were higher than direct costs in all severity stages. For direct costs, main cost drivers were hospitalizations in stage III and IV, and drugs in stage I and II, respectively. The main cost driver in indirect costs was productivity loss due to early retirement, except in stage I where the driver was sick-leave. In comparison with a similar study performed in 1999 a numerical increase in mean annual total costs per patient was observed (ns).

Conclusions: The results indicate that the societal costs of COPD in Sweden are substantial, and the costs increase considerably by disease severity.

Place, publisher, year, edition, pages
2011. Vol. 38, no Suppl 55
National Category
Respiratory Medicine and Allergy
URN: urn:nbn:se:umu:diva-103805OAI: diva2:815465
Available from: 2015-06-01 Created: 2015-06-01 Last updated: 2015-10-19Bibliographically approved

Open Access in DiVA

No full text

Other links


Search in DiVA

By author/editor
Jansson, Sven-ArneBackman, HelenaStenling, AnnaLindberg, AnneRönmark, Eva
By organisation
Department of Public Health and Clinical Medicine
In the same journal
European Respiratory Journal
Respiratory Medicine and Allergy

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 42 hits
ReferencesLink to record
Permanent link

Direct link